Head-to-head evidence
Glipizide vs Glyburide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Sulfonylurea receptor (SUR1) · full Type 2 Diabetes pipeline
Glipizide · Glucotrol
Marketed by Pfizer
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06830096 (registry estimate)
Glyburide · Diabeta / Micronase
Marketed by Pfizer
NCT00279045 · Phase 3 · completed
The large study was randomized and compared glyburide with two active treatments, but the registry does not state whether treatment was blinded and provides no results for the primary endpoint. Because the primary comparison cannot be assessed, this is considered moderate evidence rather than strong evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glipizide's landscape · Glyburide's landscape